XOMA Royalty completes acquisition of HilleVax and initiates Nasdaq delisting

XOMA Royalty Corporation has finalized its acquisition of HilleVax, Inc., making the biotech a wholly-owned subsidiary and leading to its delisting from Nasdaq. The deal, valued at $1.95 cash per share plus a contingent value right (CVR), saw 77.48% of HilleVax shares tendered and occurred while the company was trading near its 52-week high. This acquisition aligns with XOMA Royalty's broader strategic growth, which also includes an agreement to acquire LAVA Therapeutics N.V., with the CVR offering HilleVax shareholders potential future payments tied to specific financial outcomes and vaccine program proceeds.

Analysis

XOMA Royalty Corporation has successfully completed its acquisition of HilleVax, Inc. (HLVX), a transaction that underscores a key part of its strategic growth initiative within the biotech sector. The deal was structured as a tender offer of $1.95 in cash plus a non-transferable contingent value right (CVR) per share, a price point near HilleVax's 52-week high which likely contributed to the strong acceptance rate of 77.48% of outstanding shares. As a result of the merger, HilleVax will be delisted from Nasdaq and its entire board and management, including the CEO and CFO, have been replaced, marking a complete operational and governance takeover by XOMA. The CVR provides former HLVX shareholders with potential upside tied to specific outcomes, including the monetization of HilleVax's norovirus vaccine programs and realization of excess cash above a $102.95 million threshold. This acquisition, coupled with XOMA's concurrent agreement to acquire LAVA Therapeutics N.V., signals an aggressive expansion phase for XOMA, focused on accumulating royalty-bearing assets.

Key Decisions for Investors

• Former HilleVax shareholders must now assess the potential value of the non-transferable CVR, as their future returns are exclusively tied to XOMA's ability to successfully monetize HilleVax's residual cash and vaccine programs.
• Investors in XOMA Royalty should view this as a successful execution of its acquisition strategy and monitor the integration of HilleVax's assets, as well as progress on the parallel acquisition of LAVA Therapeutics, for signs of effective capital deployment.
• With HilleVax now delisted and trading suspended, market participants should close out any remaining positions and recognize that the company no longer exists as a publicly traded entity, shifting focus to XOMA's expanded portfolio and strategy.